Vir Biotechnology and Gilead Enter $1.87B Oncology Collaboration Deal

Key Facts

1Vir Biotechnology entered into a collaboration agreement with Gilead to develop novel T-cell engagers for solid tumors.

2The deal is valued at up to $1.87 billion in potential payments plus royalties.

Vir Biotechnology entered into a collaboration agreement with Gilead to develop novel T-cell engagers for solid tumors, Benzinga reported. The deal is valued at up to $1.87 billion in potential milestone payments plus royalties. The partnership aims to leverage the combined expertise of both companies to advance oncology treatments through strategic research and development.

VIR closed at $10.61 on October 13, 2026, having traded between a day high of $11.25 and a day low of $10.6 during that session. This milestone-heavy agreement provides substantial capital potential and industry validation for Vir Biotechnology as it advances its clinical pipeline in the oncology space.